Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

5.36
-0.0700-1.29%
Post-market: 5.360.00000.00%19:30 EDT
Volume:276.67K
Turnover:1.50M
Market Cap:320.96M
PE:-5.36
High:5.53
Open:5.45
Low:5.27
Close:5.43
52wk High:5.78
52wk Low:2.20
Shares:59.88M
Float Shares:33.00M
Volume Ratio:0.45
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9995
EPS(LYR):-1.1091
ROE:-397.30%
ROA:-45.73%
PB:16.61
PE(LYR):-4.83

Loading ...

Orchestra BioMed Q1 revenue falls and misses estimates

Reuters
·
May 13

BRIEF-Orchestra BioMed Q1 EPS USD -0.33

Reuters
·
May 13

Orchestra Biomed Q1 EPS USD -0.33

THOMSON REUTERS
·
May 13

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

GlobeNewswire
·
May 13

Press Release: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Dow Jones
·
May 13

Orchestra BioMed Q1 net loss widens 10% to $20.7 million; revenue drops 87% to $110,000

Reuters
·
May 13

Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Orchestra BioMed Holdings (OBIO)

TIPRANKS
·
May 12

Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline

TIPRANKS
·
May 12

Orchestra BioMed targets BACKBEAT trial enrollment completion by end-Q3 2026

Reuters
·
May 12

U.S. Earnings Preview: After Market Close May 8

Dow Jones
·
May 09

Orchestra BioMed receives $15M payment from Ligand

TIPRANKS
·
May 07

Press Release: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

Dow Jones
·
May 06

Orchestra Biomed Receives $20 Million Payment From Medtronic Under Previously Announced Financing Agreement

THOMSON REUTERS
·
May 06

Orchestra Biomed Holdings Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
May 02

Orchestra granted additional breakthrough device designation for AVIM therapy

TIPRANKS
·
May 01

Orchestra BioMed wins FDA Breakthrough Device designation for AVIM hypertension therapy

Reuters
·
Apr 30

FDA Grants Orchestra Biomed Additional Breakthrough Device Designation for Avim Therapy

THOMSON REUTERS
·
Apr 30

RTW Investments reports disposal of 32 Orchestra BioMed shares for $132.16

Reuters
·
Apr 30

Orchestra BioMed says MODERATO II trial shows 13.2 mmHg AVIM blood pressure drop

Reuters
·
Apr 24

Orchestra BioMed presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy

Reuters
·
Apr 06